Cancer Drug Zevalin May Finally Thrive Under Spectrum
This article was originally published in The Pink Sheet Daily
Executive Summary
The small oncology company may be able to succeed with the non-Hodgkin lymphoma drug where others have failed.
You may also be interested in...
Spectrum’s Zevalin Still Living In Rituxan’s Shadow, FDA Advertising Letter Shows
FDA citations of Rituxan comparisons in a promotion for Zevalin throw added salt on old wounds for drug that has taken backseat to Rituxan’s blockbuster story.
Radiotherapeutics Market Snapshot: This Sector Is Getting Hot
The radiotherapeutics sector is attracting a new and diverse group of biopharma players hoping to capitalize on the potential advantages offered by newer therapeutic radioisotopes.
Spectrum Hopes For Synergies With Allos Acquisition Amid Phase III Setback
Spectrum issued a tender offer of $1.82 per share for Allos Therapeutics on the same day that it announced the Phase III failure of its bladder cancer drug.